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probability of OS was 45% (95% CI 33-57%) for the whole group.
OS for AML and MDS was 42% (95% CI 28-56%) and 49% (95%
CI 31-76%) (P0.4). In multivariate analyses, the factors associated
with worse OS were: More than 5% blast at SCT (HR 2.1 95% CI
1.1-4.2; P0.03) and the absence of chronic GVHD (HR 4.7, 95%
CI 2.3-9.5; P0.001) Conclusion: Our results supports the use of
RIC Allo-SCT as a curative option for those patients with high risk
NRM for conventional allo-SCT but who can beneﬁt from GVL
effect.
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Busulfan-based conditioning therapy is used for hematologic
malignancies prior to hematopoietic stem cell transplantation
(HSCT). A major obstacle to successful HSCT is post-transplant
recurrence of the disease. We hypothesize that a) inherent genet-
ically determined factors in the leukemic cell population have a
major contributory role in such treatment failure, and b) leukemic
cell gene expression proﬁling can be used to dissect factors that
contribute to cellular busulfan (Bu) resistance. Two Bu-resistant
myeloid leukemia cell lines were established through intermittent
exposure to gradually increasing Bu concentrations. The cells were
characterized and analyzed by microarray and real time PCR tech-
niques to identify genes that were differentially expressed in Bu
resistant (KBM7/B5-Bu2506 and KBM3-Bu2506) and parental
sensitive cells. The resistant cell lines are 4-5 fold more resistant
than their respective parental lines and evade Bu-mediated G2-
arrest and apoptosis, which is consistent with up-regulation of
anti-apoptotic genes including BCL-XL, BAG3, BCL2, BCL2A1,
and BCL2L10 and down-regulation of pro-apoptotic genes includ-
ing BID, BAX, BNIP3, BCL2L11, BIK, LTBR and TNFSF7. Expo-
sure to Bu did not activate caspases in the Bu resistant cells. This
is in contrast to what was seen in the parental drug-sensitive lines,
where Bu-induced apoptosis was mediated through activation of
caspases and additional hitherto unidentiﬁed mechanisms. Inhibi-
tion of caspases by Z-VAD-FMK completely inactivated PARP1
cleavage and reduced apoptosis by 50%. The Bu resistance of
Bu2506 cells may include up-regulation of the HSP90 protein.
Inhibition of HSP90 with geldanamycin made Bu2506 cells signif-
icantly more sensitive to Bu. The signiﬁcance of our observations
was conﬁrmed in cell samples derived from AML patients with
“chemotherapy refractory” AML who rapidly had failed allogeneic
stem cell transplantation following a high-dose Bu-based condi-
tioning program, as compared with leukemic cell gene proﬁles
from patients who after HSCT have remained in remission for
more than one year. We conclude that apoptotic signaling mech-
anisms and HSP90 expression may have important clinical roles in
treatment (i.e. allo-HSCT) failure after high-dose Bu-based con-
ditioning therapy and point to a potential beneﬁt for investigating
apoptosis altering small molecules together with alkylating agents
in this setting. (Supported by NIH grant P01 CA055164).
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